Characteristics of anti-TNF treated patients with lymphoma/leukaemia
Treatment Initiating year | Sex | Year of birth | Rheumatic disease | Previous DMARD* | Continuing DMARD at anti-TNF initiation | Therapeutic response to anti-TNF | Tumour diagnosis | Outcome course Oct 2003 | ||
---|---|---|---|---|---|---|---|---|---|---|
Diagnosis | Onset | Time of diagnosis | Anti-TNF treatment day at diagnosis | |||||||
*MTX, methotrexate; SSZ, sulfasalazine; ciclosp, ciclosporin; ama, antimalarial drugs; gold IM, injectable gold; gold oral, auranofin; CYC, cyclophosphamide. | ||||||||||
Infliximab | M | 1923 | RA | 1972 | 2 | 0 | +? | Hodgkin | 129 | Fatal |
July 2000–Nov 2000 | SSZ, ama | Nov 2000 | Nov 2000 | |||||||
Infliximab Apr 2000–Dec 2002 | F | 1926 | RA, keratitis | 1978 | 2 MTX, CYC | MTX | ++ | Non-Hodgkin Maxilla | 180 | Alive |
Oct 2000 | ||||||||||
Infliximab Feb 2000–Sep 2001 | F | 1943 | RA | 1989 | 6 MTX, SSZ, gold IM and oral, ama | 0 | +++ | Non-Hodgkin, B-lcc, inguinal | 570 | Alive |
Sep 2001 | ||||||||||
Infliximab, then etanercept Mar 1999–Sep 1999, Sep 1999-Aug 2002, respectively | F | 1954 | RA | 1989 | 5 MTX, SSZ ciclosp, gold IM, penicillamine | MTX | +++ | MALT, lung Aug 2002 | 1081 | Fatal Postmortem MALT diagnosis in Aug 2002 |
Etanercept Apr 1999–Dec 1999 | F | 1918 | RA | 1994 | 3 MTX, SSZ, gold IM | 0 | +? | Immuno-cytoma, breast Dec 1999 | 220 | Fatal June 2000 |
Etanercept Apr 1999–July 2000 | M | 1925 | RA | 1976 | 1 MTX | MTX | ++ | Acute myeloic leukaemia, trisomi 8 chromosome | 440 | Moved abroad, fatal Jan 2002 |
Nov 2000 |